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Abstract
Background: The molecular mechanisms that regulate the entry of dietary sterols into the body
and their removal via hepatobiliary secretion are now beginning to be defined. These processes are
specifically disrupted in the rare autosomal recessive disease, Sitosterolemia (MIM 210250).
Mutations in either, but not both, of two genes ABCG5 or ABCG8, comprising the STSL locus, are
now known to cause this disease and their protein products are proposed to function as
heterodimers. Under normal circumstances cholesterol, but not non-cholesterol sterols, is
preferentially absorbed from the diet. Additionally, any small amounts of non-cholesterol sterols
that are absorbed are rapidly taken up by the liver and preferentially excreted into bile. Based upon
the defects in sitosterolemia, ABCG5 and ABCG8 serve specifically to exclude non-cholesterol
sterol entry at the intestinal level and are involved in sterol excretion at the hepatobiliary level.
Methods: Here we report the biochemical and immuno-localization of ABCG5 and ABCG8 in
human liver, gallbladder and intestine using cell fractionation and immunohistochemical analyses.
Results: We raised peptide antibodies against ABCG5 and ABCG8 proteins. Using human liver
samples, cell fractionation studies showed both proteins are found in membrane fractions, but they
did not co-localize with caveolin-rafts, ER, Golgi or mitochondrial markers. Although their
distribution in the sub-fractions was similar, they were not completely contiguous.
Immunohistochemical analyses showed that while both proteins were readily detectable in the
liver, ABCG5 was found predominately lining canalicular membranes, whereas ABCG8 was found
in association with bile duct epithelia. At the cellular level, ABCG5 appeared to be apically
expressed, whereas ABCG8 had a more diffuse expression pattern. Both ABCG5 and ABCG8
appeared to localize apically as shown by co-localization with MRP2. The distribution patterns of
ABCG5 and ABCG8 in the gallbladder were very similar to each other. In the small intestine both
ABCG5 and ABCG8 appear to line the brush border. However, at the level of the enterocyte, the
cellular distribution patterns of ABCG5 and ABCG8 differed, such that ABCG5 was more diffuse,
but ABCG8 was principally apical. Using standard deglycosylation methods, ABCG5 and ABCG8
do not appear to be glycosylated, suggesting a difference between human and mouse proteins.
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Conclusion: We report the distribution patterns of ABCG5 and ABCG8 in human tissues. Cell
fractionation studies showed that both proteins co-fractionated in general, but could also be found
independent of each other. As predicted, they are expressed apically in both intestine and liver,
although their intracellular expression patterns are not completely congruent. These studies
support the concept of heterodimerization of ABCG5 and ABCG8, but also support the notion
that these proteins may have an independent function.
Background
The gastrointestinal tract is the initial barrier to dietary
constituents and is important in regulating nutrient entry,
as well as keeping non-nutrients out. Additionally, the
hepatobiliary system acts as an additional filter to rapidly
excrete such non-nutrients into bile, thus keeping the net
retention of these potential toxins low. Mammals have
evolved many mechanisms in the gastrointestinal tract to
select out usable dietary constituents from those that
maybe potentially toxic to the body. It is apparent that the
ATP-binding cassette proteins (ABC proteins/transport-
ers) are the machinery that mediate the ATP-dependent
transport of a wide variety of substrates that range from
xenobiotics to peptide fragments [1]. A subset of these
ABC transporters, located in the canalicular membranes of
mammalian liver, play key roles in bile formation and
detoxification [1-3].
One of these processes involves the regulation of sterol
entry and excretion. Whole body cholesterol homeostasis
is a tightly regulated process, involving dietary absorp-
tion, de novo synthesis and hepatobiliary secretion. Sito-
sterolemia, a rare autosomal recessive disorder of sterol
metabolism results in the disruption of dietary sterol entry
and hepatobiliary sterol secretion [4-6]. Under normal cir-
cumstances, our diets contain equal amounts of plant
sterols and cholesterol, but the plant sterols are specifi-
cally excluded from our bodies and only regulated
amounts of cholesterol are retained. In Sitosterolemia,
this exclusion is defective resulting in the retention of
non-cholesterol sterols. Mutations in either, but not both,
of two ABC transporters, ABCG5 and ABCG8, encoded by
a single locus, STSL, are known to cause this disease [7-9].
Based upon the genetics, as well as in vitro and in vivo data,
these 'half-transporters' are proposed to function as obli-
gate heterodimers. In vitro experiments have shown that
both proteins are needed to be co-expressed for apical
expression and that these may function as mutual chaper-
ones in the ER for maturation [10,11]. In vivo experiments
in mice have not been consistent. Using the Abcg5/Abcg8
double knockout mice, Graf et al has shown that by inoc-
ulating them with adenoviral constructs for Abcg5 and
Abcg8 that both are required for expression of both pro-
teins [11]. Additionally, Plosch et al and our group have
constructed mouse models deficient in either Abcg5 [12]
or Abcg8 [13] that show different biliary physiology than
that of the Abcg5/Abcg8 double knockout mice. This sug-
gests these proteins may have independent function(s) in
addition to their function as heterodimers. However, to
date, no reports of characterization and localization of the
human proteins have been reported.
In this report, we examined the location of these two pro-
teins using cellular fraction and immunohistochemical
analyses of human liver, gallbladder and small intestine.
We found a general concordance of co-expression of both
proteins, but we also noted that ABCG5 and ABCG8 could
be found in plasma membranes, as well as in intracellular
membrane locations independent of each other. Addi-
tionally, deglycosylation of human liver membranes with
peptidyl N-glycosidases did not alter the mobility of the
proteins after SDS-PAGE, suggesting that these proteins
may not be glycosylated in human liver. This differential
localization suggests that perhaps ABCG5 and ABCG8
may have functions independent of each other, as well as
functioning as heterodimers.
Methods
Tissue aquistion. Human liver donated for transplanta-
tion, but deemed unsuitable for transplantation on
inspection by the transplant service (usually based upon a
'fatty' appearance) was obtained in accordance with IRB
approval. As soon as the liver was deemed unsuitable
(typically less than 10 h following harvesting) pieces were
either snap-frozen in liquid nitrogen and stored at -80°C
or liquid nitrogen until use, or placed in ice-cold 2-meth-
ylbutane and stored in liquid nitrogen. Samples from
more than nine different donors were used in these stud-
ies. Additionally, human gallbladders and segments of
proximal small intestine were obtained from patients
under going either laproscopic cholecystectomy or pan-
creatoduodenectomy (Whipple procedure). These tissues
were directly taken from the operating room in normal
saline on ice to be processed directly for frozen sectioning.
Antibodies
Anti-membrin, anti-transferrin, and anti-calnexin anti-
bodies were obtained from Stressgen (Victoria, BC Can-
ada), anti-caveolin antibody from BD Bioscience (San
Diego, CA, USA), anti-MDR1 that also detects MDR2/3
(C219) from Centocor Inc. (Malvern, PA, USA), anti-
MRP2 (cMOAT) from Chemicon InternationalBMC Gastroenterology 2004, 4:21 http://www.biomedcentral.com/1471-230X/4/21
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(Temecula, CA, USA) and secondary antibodies were pur-
chased from Jackson Immuno research (West Grove, PA,
USA). Polyclonal rabbit anti-sera to human ABCG5 and
ABCG8 peptides were generated in-house, using a 20-pep-
tide immunogen from human ABCG5 (576–587, FQKYC-
SEILVVNEFYGNFTC, GenBank Accession number
NP_071881) and a 22-peptide sequence from human
ABCG8 (608–629, SRRTYKMPLGNLTIAVSGDKIL, Gen-
Bank Accession number NP_071882). The anti-sera were
further purified using peptide affinity columns and stored
at a concentration of 0.8 mg/ml in Immuno Pure Binding
Buffer (Pierce, Rockford, IL, USA). For peptide blocking
experiments the peptides were dissolved in DMSO (final
concentration 30%), incubated with the corresponding
peptide for 1 1/2 hours at 37°C then used for immunob-
lotting as described below.
Membrane protein preparation
Crude total membrane isolation was carried out with
minor modifications as previously described [14]. All the
procedures were carried out at 4°C. Three grams of
human liver were homogenized in homogenization
buffer (5 mM Tris pH7.5, 250 mM sucrose, 1 mM PMSF,
20 µg/µl of leupeptin and 1 µg/µl of aprotinin) by apply-
ing 10 strokes with a dounce homogenizer. The homoge-
nate was centrifuged at 1000 g for 10 minutes, the pellet
containing any undisrupted cells and nuclear debris were
re-homogenized with one-half the initial volume of
homogenization buffer, centrifuged at 1000 g for 10 min-
utes and this process was repeated once more. Superna-
tants were pooled and subjected to centrifugation at
100,000 g for 40 minutes. The resulting pellet, deemed the
crude membrane fraction, was used as the starting mate-
rial for Western blotting and fractionation experiments.
Nycodenz gradient fractionation
Human liver crude total membrane proteins were re-sus-
pended in 30% Nycodenz solution (Nycodenz in 5 mM
Tris-HCl pH 7.5 and 1 mM EDTA). This suspension was
loaded on top of a 40% Nycodenz solution cushion in an
ultracentrifuge tube, overlaid by consecutive 23%, 20%,
15% and 10% Nycodenz solutions and subjected to cen-
trifugation at 39,000 rpm for 16 hours at 4°C in a SW41
rotor (Beckman Instrument, Palo Alto, CA). After centrif-
ugation, 800–1000 µl fractions were sequentially
removed from the top, combined with two volumes of
homogenization buffer (see above) and centrifuged at
39,000 rpm at 4°C for 40 minutes to remove the
Nycodenz. The resulting pellets were re-suspended in
buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tri-
ton X-100 and 0.1% SDS, 1 mM PMSF, 20 µg/µl of leu-
peptin and 1 µg/µl of aprotinin), the protein content
determined by the method of Lowry and fractions ana-
lysed by SDS-PAGE. Equal amounts of protein (25 µg) per
lane were loaded.
Sucrose gradient fractionation
The procedure for membrane fractionation was essentially
as described for the Nycodenz fractionation, except for the
homogenization buffer used (25 mM Tris pH6.8, 150 mM
NaCl, 1 mM PMSF, 20 µg/µl of leupeptin and 1 µg/µl of
aprotinin). The sucrose density gradient fractionation was
modified as previously described [15-17]. Human liver
crude membrane proteins were re-suspended in 1% Tri-
ton X100 buffer (25 mM Tris-HCl pH6.5, 150 mM NaCl,
1% Triton X100, 1 mM PMSF, 20 µg/µl of leupeptin and
1 µg/µl of aprotinin), adjusted to a final sucrose concen-
tration of 40% and overlaid with a 15–30% linear sucrose
gradient. The samples were subjected to centrifugation at
39,000 rpm for 16 hours at 4°C in a SW41 rotor (Beck-
man Instrument, Palo Alto, CA, USA) and fractions col-
lected from the top as described above. The proteins from
fractions 1–4 from top of the tube were precipitated with
acetone because these fractions did not contain sufficient
protein for direct analysis. After protein concentrations
were determined, equal amounts of proteins (20 µg) from
each fraction were resolved by SDS-PAGE.
Immunoblotting
Proteins resolved by SDS-PAGE were transferred onto
nitrocellulose membranes. Membranes were then blocked
for 1 hour in 5% dry milk in PBS-T (Phosphate Buffered
saline and 0.1% Tween 20) and incubated with primary
antibody against either ABCG5 or ABCG8 in 5% milk in
PBS-T overnight at 4°C. Blots were washed three times for
5 minutes in TBS-T (Tris Buffered Saline/0.1% Tween-20)
with 150 mM NaCl, incubated with goat-anti-rabbit con-
jugated HRP antibodies (1:10000 dilution), washed for
three times 5 minutes and developed with Western Light-
ning®  Chemiluminescence Reagent Plus (Perkin Elmer
Life Sciences, Inc. Boston, MA, USA).
Immunohistochemical analysis and microscopy
Snap-frozen liver, gallbladder and intestine tissues were
used to cut 8 µm thick frozen sections, air-dried for 30
minutes onto glass slides and kept at -80°C until used.
The slides were stained with hematoxylin, rinsed with PBS
three times, fixed for 10 minutes with cooled methanol at
-20°C and rinsed with PBS three times. The slides were
treated with blocking solution (10% donkey serum in 0.1
M glycine/PBS) for 30 minutes at room temperature and
incubated with primary antibody overnight at 4°C. The
slides were washed with PBS and incubated with second-
ary antibody (goat-anti-rabbit conjugated with Cy3™ or
rhodamine or FITC) for 20–30 minutes at room tempera-
ture, rinsed with PBS three times and examined under an
Olympus BX-5 confocal microscope with Fluoview.BMC Gastroenterology 2004, 4:21 http://www.biomedcentral.com/1471-230X/4/21
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Results
Identification of ABCG5 and ABCG8 in crude total 
membrane preparations of human liver
Peptide antibodies were raised against human ABCG5
and human ABCG8 and affinity purified prior to use (see
Methods). The immunogen peptides used for the antibod-
ies were selected since they were sequences that lay out-
side of the predicted transmembrane domains and based
upon antigenicity.Western blotting experiments (Figure
1A) showed that both anti-ABCG5 and anti-ABCG8 anti-
bodies bound to ~75 kDa proteins in human liver crude
membranes. Pre-immune sera did not detect the ~75 kDa
expected bands. Pre-incubation of the immune antibodies
with the peptides against which they were raised abol-
ished specific binding (Figure 1B). For anti-ABCG5 5 µg of
peptide was needed to block 1 µg of antibody and for anti-
ABCG8 12.5 µg of peptide was needed to block 1 µg of
antibody. Interestingly, a ~60 kDa band was detected
using the anti-ABCG8 antibody whose signal is abolished
when incubated with the peptide from which the anti-
body was raised (Figure 1B and 1C, arrow indicated
band). The significance of this is unclear at present. These
antibodies were also tested against mouse and rat liver
membrane preparations and no significant cross-reactiv-
ity was detected except for faint bands seen with anti-
ABCG5 in mouse liver samples (Figure 1A, tracks 3 and 4).
No other bands were detected above the 150 kDa marker
in all western blots. Interestingly, while these proteins are
predicted to be N-glycosylated [8,9], only single bands in
the appropriate molecular weight range were detected and
no higher molecular bands were observed. To investigate
whether these proteins are glycosylated, crude membrane
fractions were digested with EndoH, PNGase F and exam-
ined for alterations in gel migration by SDS-PAGE (Figure
1C). Although the mobility of a known glycoprotein,
transferrin, was increased in the same fractions following
deglycosylation, there was no change in the mobility of
ABCG5 or ABCG8 (Figure 1C).
Localization of ABCG5 and ABCG8 by Nycodenz and 
Sucrose gradient fractionation of human liver
Crude total membrane proteins from human liver were
fractionated by Nycodenz gradient centrifugation and
examined for localization markers by western blot analy-
ses (Figure 2A). After Nycodenz gradient centrifugation,
ABCG5 (fractions 9–10) and ABCG8 (fractions 6–11)
were found to have a broad range of distribution and
appeared to be distributed in a pattern similar to calnexin
(an ER membrane marker, fractions 5–10), Cytochrome C
(a mitochondrial marker, fractions 4–9), transferrin (a
plasma membrane marker, fractions 1–11), caveolin
(fractions 6–10) and MDR1 (an apical membrane marker,
fractions 4–10). ABCG5 and ABCG8 did not co-localize
with cis-Golgi (Figure 2A) markers.
To examine whether ABCG5 and ABCG8 were associated
with membrane rafts, total membrane proteins from
human liver were solubilized with ice-cold 1% Triton X-
100 detergent and fractionated by sucrose density gradi-
ent centrifugation (Figure 2B). Fractionation resulted in
two Triton X-100 insoluble complexes, as judged by the
clarity of the gradient fractions. The first was found in the
low-density range (15–20% sucrose, fractions 2–6, Figure
2B) and the second in the high-density range (40%
sucrose, fractions 10–12, Figure 2B). Caveolin-rich frac-
tions localized to the low-density range (Figure 2B, frac-
tions 2–6). However, ABCG5 and ABCG8 were detected in
the high-density fractions, F10–12, along with transferrin
(fractions 5–12) and MDR1 (fractions 9–11). Calnexin or
cytochrome C, under these conditions did not co-localize
with either ABCG5 or ABCG8. Note that the majority of
the ABCG5 and ABCG8 were present in the densest frac-
tions, F11–12. Under these conditions, membrin, a cis-
Golgi membrane marker, was also detected in fraction 12.
Thus, ABCG5 and ABCG8 have significant overlap with
each other suggesting co-localization. However, these pro-
teins did not seem to co-localize with any specific mem-
brane marker except transferrin, when two different
methods of fractionation were utilized.
Immunohistochemical localization of ABCG5 and ABCG8 
in human liver
It has been shown previously that ABCG5 and ABCG8 are
expressed only in the liver and intestine [8,9]. To further
characterize the location of ABCG5 and ABCG8 in human
liver, immunohistochemical analyses were performed on
frozen serial sections of human liver. Pre-immune sera
were used as negative controls. The distribution of the two
proteins appeared to be divergent not only histologically,
but also at the cellular level. From a histological point of
view, ABCG5 was detected along sinusoidal tracts (Figure
3A, upper panel) whereas ABCG8 was detected within the
cells lining the bile ducts (Figure 3B, upper panel). At
higher magnification, ABCG5 was detected along bile
canaliculi and at the cellular level appeared to be an api-
cally expressed (Figure 3A, lower panel). However, the
distribution of ABCG8 at the cellular level appeared more
diffuse consistent with plasma membrane expression and
perhaps in intracellular membranes (Figure 3B, lower
panel). Expression of ABCG5 within intracellular vesicu-
lar compartments could not be excluded by the tech-
niques employed. To confirm an apical location of
ABCG5 and ABCG8 immunohistochemical co-localiza-
tion studies were carried out using an antibody against a
known apical transporter (MRP2) in the liver. As shown in
Figure 4, ABCG5 and ABCG8 have significant overlap in
expression with MRP2 (panels A and B, respectively).BMC Gastroenterology 2004, 4:21 http://www.biomedcentral.com/1471-230X/4/21
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Immunohistochemical localization of ABCG5 and ABCG8 
in human gall bladder
Serial sections of human gall bladder were incubated with
each antibody and pre-immune serum was used as a neg-
ative control. Both ABCG5 and ABCG8 were detected in
the epithelium of gall bladder mucosa (Figure 5A and 5B).
At higher magnification, the cellular distribution of the
signals detected was similar and showed a diffuse cyto-
plasmic distribution (Figure 5A and 5B).
Immunohistochemical localization of ABCG5 and ABCG8 
in human small intestine
Both ABCG5 and ABCG8 were detected in the apical sur-
faces of the enterocytes in biopsy samples of the small
intestine (Figure 6A and 6B, upper panels). However, at
higher magnification the cellular distribution of ABCG5
appeared more diffuse (Figure 6A, lower panel) whereas
ABCG8 was expressed apically (Figure 6B, lower panel).
This divergent pattern was seen in all of the serial sections
analyzed.
Immunoblotting analyses of ABCG5 and ABCG8 in human liver Figure 1
Immunoblotting analyses of ABCG5 and ABCG8 in human liver. Panel A shows the immunodetection of ABCG5 
(tracks 1–6), ABCG8 (tracks 7–12) in membrane preparations from human liver (HL, tracks 1, 2, 7, 8) mouse liver (ML, tracks 
3, 4, 9, 10) or rat liver (RL, tracks 5, 6, 11, 12). The anti-ABCG5 peptide antibody detected a faint mouse band, but no other 
specific binding was identified. Although the pre-immune sera detected bands in the rodent tissue samples, none were detected 
in human liver (tracks 13–16, MB, mouse brain). Specificity was further shown by pre-incubation of the antibodies with the pep-
tides they were raised against (panel B). In the presence of the specific peptides, the 75 kDa bands are not detected in human 
liver microsomes. Panel C shows the results of deglycosylation of human total liver microsomes, probed with anti-ABCG5 (left 
hand panel), anti-ABCG8 (middle panel) or anti-transferrin (right hand panel). Aliquots from the same incubation were sepa-
rated for all three western blots. Although ABCG5 and ABCG8 do not appear to have their SDS-PAGE mobility's altered by 
either EndoH or PNGase F treatment, that of transferrin in the same samples is clearly effected (see Text for discussion). 
Newly synthesized (sensitivity to EndoH), as well as mature forms of transferrin (resistant to EndoH, but fully sensitive to 
PNGase F) are present in the liver membrane preparations.
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Discussion
In this study, we report the localization of ABCG5 and
ABCG8 in human liver, gall bladder and intestine. Our
studies showed that these proteins are highly specific in
the cells they are expressed. In the liver, expression is seen
in cells lining the hepatobiliary tracts, both hepatocytes
and ductal cells. In the intestine, robust expression was
seen only in the villus enterocyte layers. In the gall blad-
der, expression was confined to the epithelial cells lining
the lumen. However, some differences in the distribution
of ABCG5 and ABCG8 within these tissues were apparent.
In the liver, ABCG8 was highly expressed in the hepato-
cytes lining the bile ducts, whereas ABCG5 was more
robustly expressed in hepatocytes lining the cannaliculae.
In fractionation studies, using two different methods of
separation, the distribution of ABCG5 and ABCG8 was
compatible with both proteins potentially acting as het-
erodimers. However, we also noted that there were frac-
tions where only one of these proteins, but not the other
was detected. This could be an artefact, with one antibody
Subcellular localization of ABCG5 and ABCG8 in human liver Figure 2
Subcellular localization of ABCG5 and ABCG8 in human liver. Panel A shows the Nycodenz gradient fractionation 
and panel B the Triton X-100/sucrose gradient fractionation. A representative result from each of these is shown. F1–F12 rep-
resents serial fractions collected from the top of the tube. Proteins from each of these fractions were separated by SGS-PAGE, 
western blotted and probed for the proteins as indicated on the figure. Calnexin (ER marker), membrin (Golgi marker) and 
caveolin (raft marker) did not co-localize with ABCG5/ABCG8 when both biochemical fractionation patterns are compared. 
However, MDR1 (apical membrane marker) and transferrin (plasma membrane marker) showed some consistency with 
ABCG5/ABCG8 co-localizations (tracks F9–10, panel A and F11, panel B).
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Immunolocalization of ABCG5 and ABCG8 in human liver sections Figure 3
Immunolocalization of ABCG5 and ABCG8 in human liver sections. Panel A shows the staining pattern of ABCG5 
and panel B that for ABCG8. The pre-immune controls for both antibodies are as marked and shown in the top right hand cor-
ners of each panel. The top panels of each section are at low magnification (bar is 50 µm) and the bottom panels at high magni-
fication (10 µm). The images for ABCG5 and ABCG8 were visualised with red and green colors respectively using Adobe 
Photoshop (Adobe, Cupertino, CA). The left panels show hematoxylin stained phase contrast images and the middle panels 
show the fluorescence images after immune serum staining. The bottom right panel of each section shows the merged images 
of phase contrast and the fluorescence signals. ABCG5 was readily detectable in canalicular cells and at higher magnification 
seemed to be apical in expression (panel A). On the other hand, ABCG8 was more readily detectable in cells lining the bile 
ducts (panel B, top panels), as well as in canalicular cells; although its cellular expression appeared more diffuse (see Text for 
discussion).
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Co-localization of ABCG5 and ABCG8 with MRP2 by immunohistochemistry Figure 4
Co-localization of ABCG5 and ABCG8 with MRP2 by immunohistochemistry. Liver sections were simultaneously 
incubated with either the combination of anti-ABCG5/MRP2 or anti-ABCG8/MRP2. Panel A shows staining patterns of MRP2 
and ABCG5 independently (upper portion) then merged together (lower right) with what appears to be similar over-lapping 
expression patterns. Likewise MRP2 and ABCG8 expression patterns appear to over lap as well as shown in panel B. Bar is 20 
µm.
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Immunolocalization of ABCG5 and ABCG8 in human gall bladder sections Figure 5
Immunolocalization of ABCG5 and ABCG8 in human gall bladder sections. Gall bladder surgical samples were 
stained for ABCG5 (panel A, red staining) or ABCG8 (panel B, green staining). The layout is as indicated for figure 3. Both 
ABCG5 and ABCG8 appeared to be confined to the epithelial cells lining the lumen and no significant staining in any of the 
deeper cell layers was detected. At the cellular level, both proteins seem to be diffusely expressed within the cell and at plasma 
membrane. A strict apical expression was not observed for either of these proteins.
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Immunolocalization of ABCG5 and ABCG8 in human intestinal sections Figure 6
Immunolocalization of ABCG5 and ABCG8 in human intestinal sections. Human intestinal surgical samples were 
stained with ABCG5 (panel A, red staining) or ABCG8 (panel B, green staining). The layout is as indicated for figure 3. At the 
cellular level, ABCG5 was expressed in a more diffuse pattern (panel A, see bottom right hand panel). In contrast, ABCG8 was 
expressed in the apical surfaces of the enterocytes (panel B, bottom right hand panel). Both proteins seemed to be expressed 
only in the enterocytes lining the villi and no significant expression was detected in any of the other cell layers.
$
%
P
3UHLPPXQH
P
3UHLPPXQH
P P
P P P
P P
P P PBMC Gastroenterology 2004, 4:21 http://www.biomedcentral.com/1471-230X/4/21
Page 11 of 12
(page number not for citation purposes)
being a better reagent, or that this pattern could truly
reflect that each of these proteins can also exist
independently, perhaps as homodimers. Overall, the dis-
tribution patterns of ABCG5 and ABCG8 in these cellular
fractionations were similar to that observed with the
plasma membrane marker transferrin and apical mem-
brane marker MDR1. Additionally, immunohistochemi-
cal analyses show that ABCG5 and ABCG8 are apically
expressed in the liver, gall bladder and intestine. In the
liver ABCG5 and ABCG8 also appear to co-localize with
the known apical protein MRP2. This confirms previous
data from Graf et al, using in vitro expression in WIF-B cells
[10], and support the contention that ABCG5 and ABCG8
are plasma membrane proteins.
These data would suggest that expression of these proteins
might not be wholly dependent upon mutual co-expres-
sion, as has been reported for the mouse and in in vitro
studies [10,11]. However, one note of caution should be
expressed. All of the liver samples analyzed were obtained
because they were unsuitable for transplantation. Most
livers were considered to be 'fatty' livers. While these livers
were not effectively diseased, that fact that they had fatty
infiltrates may have influenced the normal expression of
these two half-transports. Thus, confirmation in normal
human liver samples will be needed, though this may not
be feasible.
With that reservation in mind, our data do have important
implications for sterol trafficking in humans.
Firstly, the relatively robust and highly specific expression
of ABCG5 and ABCG8 in gall bladder epithelium con-
firms the important role of this organ in regulating biliary
secretion. In addition to the production of bile by the
liver, the gall bladder may be able to further regulate the
sterol content of bile, via ABCG5/ABCG8 activity. A simi-
lar pattern of expression has been reported in canine gall
bladder epithelial cell culture and these data confirm
these findings in human gall bladder [18].
Secondly, the differences in expression patterns of ABCG5
and ABCG8 in liver, gall bladder and intestine, though
subtle, seem to indicate the several important possibili-
ties. It is not clear which organ is of paramount impor-
tance in the human in regulating non-cholesterol sterol
retention. And it is not clear if ABCG5 and ABCG8 play a
significant role in determining cholesterol entry at the
intestinal level, though they seem to be implicated
strongly as determining sterol excretion at the level of the
hepato-biliary system. In mice deficient for Abcg5/Abcg8
or Abcg5, cholesterol absorption rates were not dramati-
cally affected [12,19,20]. Hepatobiliary excretion of all
sterols was significantly (but not completely) reduced. In
mice singly deficient for Abcg5 or Abcg8, some differences
have been reported [12,13]. In Abcg5 KO mice, following
LXR activation, sterol excretion in bile was comparable to
wild-type mice, though it is not clear if this also restored
plant sterol excretion. In contrast, although cholesterol
absorption studies for Abcg8 KO mouse have not been
reported, biliary excretion of cholesterol was dramatically
reduced and no stimulation of excretion was observed
after forced bile acid infusions. While all of these data
have been reported using different protocols (LXR activa-
tion, bile acid infusions, or static gall bladder puncture),
these data suggest that there exist other pathways for sterol
trafficking in both liver and intestine. At present it would
be speculative to assume that these 'other' pathways
involve ABCG5 or ABCG8 as homodimers, but this possi-
bility is supported by the circumstantial evidence of sepa-
rate patterns of expression of human ABCG5 and ABCG8
in these tissues.
Finally, although rodent sterolins are glycosylated and in
vitro  glycosylation is readily demonstrable, human
ABCG5 and ABCG8 did not appear to be glycosylated as
judged by deglycosylation-migration assays. It is possible
that this technique is insensitive and these proteins are
glycosylated. Alternatively, it is possible that the antibod-
ies we have raised only react with unglycosylated forms
and thus fail to detect the glycosylated forms. With respect
to the first issue, deglycosylation-migration has been
demonstrated to detect mouse glycosylated proteins and
since these proteins are highly conserved, this possibility
seems remote. With respect to the second possibility, if
our antibodies were exclusively detecting unglycosylated
(and presumably immature forms), the apical patterns of
expression of these proteins in both the liver and intestine
would seem to suggest that these proteins seem to traffic
to these specialized membranes normally. In the absence
of an independent method, and the lack of a direct assay
for function, whether these proteins form an active het-
erodimer can not be resolved at present.
Conclusion
In summary, we report the first immunolocalization of
ABCG5 and ABCG8 in human liver, gall bladder and
intestine. Our data show that these proteins are located in
membranes and can have an apical expression in all of
these tissues. Biochemical, as well as immunolocalization
studies show that while both proteins co-localize in gen-
eral, they can also seem to have expression patterns that
may be independent of each other.
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